Impact of analgesics on the risk of ovarian cancer; a systematic review and meta-analysis of cohort and case-control studies

IF 1.1 Q4 IMMUNOLOGY

Immunopathologia Persa Pub Date : 2023-08-22 DOI:10.34172/ipp.2023.40572

Javad Sadeghi, Saba Bazzazi, Farinaz Fattahi, Moloud Alsadat Mousavi, Ardeshir Tajbakhsh, Sadaf Rassouli, Siavash Sangi, Mahshad Ghezelbash, Anna Ghorbani

{"title":"Impact of analgesics on the risk of ovarian cancer; a systematic review and meta-analysis of cohort and case-control studies","authors":"Javad Sadeghi, Saba Bazzazi, Farinaz Fattahi, Moloud Alsadat Mousavi, Ardeshir Tajbakhsh, Sadaf Rassouli, Siavash Sangi, Mahshad Ghezelbash, Anna Ghorbani","doi":"10.34172/ipp.2023.40572","DOIUrl":null,"url":null,"abstract":"Introduction: Ovarian cancer is the sixth leading cancer-related mortality cause in women worldwide. Analgesics may hinder the occurrence of ovarian cancer through inflammation relief. The present study seeks to examine the relationship between analgesic consumption and ovarian cancer risk through a systematic review and meta-analysis. Materials and Methods: PubMed, Scopus, Web of Science, Cochrane databases, and Google Scholar search engines were searched for works published by May 2023 using standard keywords to collect the required data sources. Acquired data were then analyzed in STATA version14, considering a significance level of P < 0.05 in statistical tests. Results: The present meta-analysis comprised 21 studies (14 case-control and 7 cohort studies) performed on 53,755 subjects. Results indicated that taking aspirin reduced the risk of ovarian cancer by 8% (OR: 0.92; 95% CI: 0.87, 0.98), whereas other non-aspirin NSAIDs (non-steroidal anti-inflammatory drugs) did not significantly affect the ovarian cancer risk (OR: 0.91; 95% CI: 0.81, 1.02). Similar results were observed in the case of ibuprofen and acetaminophen, with non-significant relationships between the risk of ovarian cancer and with the consumption of both acetaminophen (OR: 0.95; 95% CI: 0.84, 1.08) and ibuprofen (OR: 0.76; 95% CI: 0.50, 1.14). Furthermore, the duration of analgesic consumption was not significantly linked to the risk of ovarian cancer in the case of all studied drugs. Conclusion: Among aspirin, ibuprofen, acetaminophen, and non-aspirin NSAIDs, only aspirin was found to reduce the risk of ovarian cancer in women while the other studied drugs did not influence the studied risk. However, further research is recommended to confirm the results. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023434730) and Research Registry (UIN: reviewregistry1668) websites.","PeriodicalId":13454,"journal":{"name":"Immunopathologia Persa","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunopathologia Persa","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/ipp.2023.40572","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Ovarian cancer is the sixth leading cancer-related mortality cause in women worldwide. Analgesics may hinder the occurrence of ovarian cancer through inflammation relief. The present study seeks to examine the relationship between analgesic consumption and ovarian cancer risk through a systematic review and meta-analysis. Materials and Methods: PubMed, Scopus, Web of Science, Cochrane databases, and Google Scholar search engines were searched for works published by May 2023 using standard keywords to collect the required data sources. Acquired data were then analyzed in STATA version14, considering a significance level of P < 0.05 in statistical tests. Results: The present meta-analysis comprised 21 studies (14 case-control and 7 cohort studies) performed on 53,755 subjects. Results indicated that taking aspirin reduced the risk of ovarian cancer by 8% (OR: 0.92; 95% CI: 0.87, 0.98), whereas other non-aspirin NSAIDs (non-steroidal anti-inflammatory drugs) did not significantly affect the ovarian cancer risk (OR: 0.91; 95% CI: 0.81, 1.02). Similar results were observed in the case of ibuprofen and acetaminophen, with non-significant relationships between the risk of ovarian cancer and with the consumption of both acetaminophen (OR: 0.95; 95% CI: 0.84, 1.08) and ibuprofen (OR: 0.76; 95% CI: 0.50, 1.14). Furthermore, the duration of analgesic consumption was not significantly linked to the risk of ovarian cancer in the case of all studied drugs. Conclusion: Among aspirin, ibuprofen, acetaminophen, and non-aspirin NSAIDs, only aspirin was found to reduce the risk of ovarian cancer in women while the other studied drugs did not influence the studied risk. However, further research is recommended to confirm the results. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023434730) and Research Registry (UIN: reviewregistry1668) websites.

查看原文本刊更多论文

镇痛药对卵巢癌发病风险的影响队列研究和病例对照研究的系统回顾和荟萃分析

简介：癌症是全球第六大女性癌症相关死亡原因。镇痛药可能通过炎症缓解来阻碍卵巢癌症的发生。本研究旨在通过系统回顾和荟萃分析来检验镇痛药消耗与卵巢癌症风险之间的关系。材料和方法：PubMed、Scopus、Web of Science、Cochrane数据库和Google Scholar搜索引擎使用标准关键词搜索截至2023年5月发表的作品，以收集所需的数据源。然后在STATA版本14中分析所获得的数据，考虑到统计学检验中P<0.05的显著性水平。结果：本荟萃分析包括对53755名受试者进行的21项研究（14项病例对照研究和7项队列研究）。结果表明，服用阿司匹林可降低卵巢癌症风险8%（OR:0.92；95%CI:0.87，0.98），而其他非阿司匹林类非甾体抗炎药对卵巢癌症风险没有显著影响（OR:0.91；95%CI:0.81，1.02），卵巢癌症风险与对乙酰氨基酚（OR:0.95；95%CI:0.84，1.08）和布洛芬（OR:0.76；95%CI:0.50，1.14）的服用之间无显著关系。结论：在阿司匹林、布洛芬、对乙酰氨基酚和非阿司匹林类非甾体抗炎药中，只有阿司匹林能降低女性患卵巢癌症的风险，而其他研究药物对研究风险没有影响。然而，建议进行进一步的研究来证实这一结果。注册：本研究基于PRISMA检查表编制，其方案已在PROSPERO（CRD42023434730）和研究注册处（UIN:reviewregistry1668）网站上注册。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊